Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia $(AML.AU)$ for both therapies. The presentation highlighted Galinpepimut-S $(GPS.AU)$, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival $(OS)$ notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.